Originally posted here:
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
Related Post
- CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities - January 21st, 2025
- Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - January 21st, 2025
- Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments - January 21st, 2025
- ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor - January 21st, 2025
- ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - January 21st, 2025
- Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand - January 21st, 2025
- Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - January 21st, 2025
- Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - January 21st, 2025
- Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - January 21st, 2025
- Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - January 21st, 2025
- Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing - January 21st, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 21st, 2025
- Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network - January 21st, 2025
- Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology - January 21st, 2025
- Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta - January 21st, 2025
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 21st, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 21st, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 21st, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 21st, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 21st, 2025
- Serina Therapeutics Announces Sale of UniverXome Subsidiary - January 19th, 2025
- Radiance has been selected to Present at the 2025 Biotech Showcase™ Alongside the J.P. Morgan Healthcare Conference - January 19th, 2025
- Biologic Pharmamedical Launches Innovative Functional Beverages for Health, Longevity, and Performance - January 19th, 2025
- Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders - January 19th, 2025
- Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - January 19th, 2025
- Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle... - January 19th, 2025
- Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - January 19th, 2025
- Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence - January 19th, 2025
- Scorpius Holdings Cancels Planned Reverse Stock Split - January 19th, 2025
- Cannabis Means Business (CMB), New York Global Edition, Opens Registration - January 19th, 2025
- XORTX Announces Change of Auditor - January 19th, 2025
- Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) - January 19th, 2025
- Lifecore Biomedical Announces Special Stockholder Meeting - January 19th, 2025
- Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines - January 17th, 2025
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - January 17th, 2025
- Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland... - January 17th, 2025
- Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma - January 17th, 2025
- Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - January 17th, 2025
- Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis - January 17th, 2025
- Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development - January 17th, 2025
- United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - January 17th, 2025
- Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - January 17th, 2025
- Autoimmunity BioSolutions to Present at the 2025 Sequire Investor Summit in Puerto Rico - January 17th, 2025
- Boehringer provides update on iclepertin Phase III program in schizophrenia - January 17th, 2025
- Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%) - January 17th, 2025
- Vaxil Bio Proposed Reverse Takeover With Green Date Terminated - January 17th, 2025
- Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an... - January 17th, 2025
- Scorpius Holdings Announces Reverse Stock Split - January 17th, 2025
- Codexis Appoints Christos Richards to Board of Directors - January 17th, 2025
- Illuccix® Receives European Approval - January 17th, 2025
- ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses - January 17th, 2025
- ProstaVive: Introducing ProstaVive as the New Standard of Prostate Support in 2025 - January 17th, 2025
- Junshi Biosciences Announces Toripalimab’s Approval in Australia - January 17th, 2025
- Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - January 13th, 2025
- Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement - January 13th, 2025
- Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates - January 13th, 2025
- 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway - January 13th, 2025
- Nusano Announces Isotope Availability - January 13th, 2025
- Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path - January 13th, 2025
- Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160... - January 13th, 2025
- Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine - January 13th, 2025
- Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - January 13th, 2025
- Mereo BioPharma Provides Update on Lead Clinical Programs - January 13th, 2025
- Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - January 13th, 2025
- Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference - January 13th, 2025
- scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - January 11th, 2025
- Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - January 11th, 2025
- RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025 - January 11th, 2025
- NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma - January 11th, 2025
- Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent... - January 11th, 2025
- NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - January 11th, 2025
- InflammX Therapeutics Announces Option Agreement with Bausch + Lomb - January 11th, 2025
- LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - January 11th, 2025
- Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States - January 11th, 2025
- Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors - January 11th, 2025
- Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - January 11th, 2025
- ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference - January 11th, 2025
Recent Comments